Repligen Corp (RGEN) · Oct 27, 2026 · Earnings
Repligen earnings beat as BioLife lifts 2026 guidance
Beat — Adjusted EPS $0.53 vs ~$0.46 consensus; revenue $209.3M vs ~$206.7M consensus
Repligen earnings beat Q3 estimates on stronger organic growth and margins, while the BioLife acquisition supports another 2026 guidance increase.
Repligen is a bioprocessing supplier riding a recovery in biopharma manufacturing demand while expanding into cell therapy through its October 6 BioLife acquisition. The filing says the core business is accelerating before BioLife is fully reflected, and the acquisition now adds a second growth engine. The broader setup is consistent with Repligen's push into recurring, workflow-embedded cell-therapy consumables.
| Metric | Q3 2026 | Q3 2025 | Nine months 2026 | Nine months 2025 |
|---|
| Revenue | $209.3M | $188.8M | $607.7M | $540.3M |
| Organic revenue growth | 12% | 18% | 12% | 14% |
| Adjusted EPS | $0.53 | $0.46 | $1.55 | $1.23 |
| Adjusted operating margin | 15.9% | 14.2% | 16.0% | 13.3% |
| Adjusted EBITDA margin | 20.9% | 19.0% | 21.0% | 18.7% |
| GAAP diluted EPS | $(0.68) | $0.26 | $(0.44) | $0.63 |
| FY 2026 adjusted revenue guidance | $844M–$852M | — | — | — |
| FY 2026 adjusted diluted EPS guidance | $2.05–$2.09 | — | — | — |
The quarter beat the published bar on both major measures. Revenue of $209.3 million exceeded the roughly $206.7 million consensus, while adjusted diluted EPS of $0.53 was well above the approximately $0.46 expectation. The beat was not just acquisition-driven: Q3 organic growth was 12%, and adjusted operating margin expanded to 15.9% from 14.2% a year earlier. The filing describes the quarter as a record, with $209million in revenue and 12.5% organic growth.
The underlying recovery is becoming more credible, though growth has not fully returned to last year's pace. Nine-month organic growth was 12% versus 14% a year ago, but profitability improved materially: adjusted operating margin rose 270 basis points to 16.0%, and adjusted EBITDA margin increased to 21.0% from 18.7%. That combination says Repligen is converting a still-improving demand environment into better operating leverage rather than merely buying growth.
Management raised the full-year outlook again, with BioLife doing part of the lifting. The new revenue midpoint of $848 million is above the prior July range midpoint of $824 million, while the new EPS midpoint of $2.07 is modestly above the prior $2.06 midpoint. The filing attributes roughly 2.5 percentage points of reported growth to inorganic contribution, primarily BioLife net of the Polymem divestiture, and says the guidance includes BioLife only from its October 6 closing. That makes the raise partly a confirmation of the already-announced deal, but the stronger organic performance and higher operating outlook are new information. The filing states that the acquisition's completion marks a milestone and that the company has already taken actions toward operating-expense synergies. 〔0〕
The GAAP loss is a real accounting drag, not the best read on current operations. Repligen posted a $38.4 million quarterly net loss and a $0.68 diluted loss per share, primarily because of a $41.2 million intangible-asset impairment charge. Adjusted net income was $29.9 million, and the company also recorded restructuring, transformation, acquisition-related and other costs. The impairment does not erase the charge, but it makes the adjusted beat and margin expansion more representative of the operating trend than the headline GAAP loss.
The strategic payoff now depends on execution, not deal completion. BioLife was already expected to close and is therefore partly known; the important next proof point is whether its recurring cell-therapy consumables and expected synergies translate into sustained organic growth and margin improvement once the business contributes for a full quarter. Repligen also opened a Seoul training and innovation center, reinforcing its push into Asian biologics and CDMO manufacturing demand, but that is supportive infrastructure rather than an immediate financial driver.
Bottom line: This is a genuine operating beat with another guidance increase, not merely a favorable acquisition presentation. The core business is recovering with better margins, while BioLife raises the longer-term growth opportunity—but integration and full-quarter contribution still have to validate the next leg of the story. (The filing's Financial Highlights, Condensed Consolidated Statements of Operations, Cash Flow Statement, and non-GAAP reconciliations provide the figures above.)
What to watch next
2027 outlook with first full-quarter BioLife contribution
Original filing on SEC EDGAR
More Repligen Corp news
